bioAffinity Technologies (BIAF) lab unit keeps College of American Pathologists accreditation

Rhea-AI Filing Summary

bioAffinity Technologies, Inc. reported that its wholly owned laboratory subsidiary, Precision Pathology Laboratory Services, has successfully maintained its accreditation from the College of American Pathologists. The continued accreditation follows an on-site inspection, indicating the lab met the standards reviewed during that visit.

The company disclosed this development in connection with a press release, which is included as an exhibit to the report.

false 0001712762 0001712762 2026-01-07 2026-01-07 0001712762 BIAF:CommonStockParValue0.007PerShareMember 2026-01-07 2026-01-07 0001712762 BIAF:WarrantsToPurchaseCommonStockMember 2026-01-07 2026-01-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 7, 2026

bioAffinity Technologies, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-41463		46-5211056
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification Number)

3300 Nacogdoches Road, Suite 216

San Antonio, Texas 78217

(Address of principal executive offices, including zip code)

(210) 698-5334

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Title of each class		Trading Symbols		Name of each exchange on which registered
Common Stock, par value $0.007 per share		BIAF		The Nasdaq Stock Market LLC (Nasdaq Capital Market)
Warrants to purchase Common Stock		BIAFW		The Nasdaq Stock Market LLC (Nasdaq Capital Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

On January 7, 2026, bioAffinity Technologies, Inc., a Delaware corporation, issued a press release announcing that its wholly owned laboratory subsidiary, Precision Pathology Laboratory Services, has successfully maintained its accreditation from the College of American Pathologists following an on-site inspection.

A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description
99.1		Press Release issued by bioAffinity Technologies, Inc., dated January 7, 2026
104		Cover Page Interactive Data File (embedded within the XBRL document)

-2-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 7, 2026	BIOAFFINITY TECHNOLOGIES, INC.
	By:	/s/ Maria Zannes
	Name:	Maria Zannes
	Title:	President and Chief Executive Officer

-3-

FAQ

What did bioAffinity Technologies (BIAF) announce in this 8-K?

bioAffinity Technologies announced that its wholly owned subsidiary, Precision Pathology Laboratory Services, has successfully maintained its accreditation from the College of American Pathologists following an on-site inspection.

Which subsidiary of bioAffinity Technologies (BIAF) is mentioned in the filing?

The filing highlights Precision Pathology Laboratory Services, a wholly owned laboratory subsidiary of bioAffinity Technologies, Inc.

What accreditation did Precision Pathology Laboratory Services maintain for bioAffinity Technologies (BIAF)?

Precision Pathology Laboratory Services maintained its accreditation from the College of American Pathologists after an on-site inspection.

Is there an exhibit included with this bioAffinity Technologies (BIAF) 8-K?

Yes. The report includes a press release as Exhibit 99.1, which is incorporated by reference, and a cover page interactive data file as Exhibit 104.

Who signed the bioAffinity Technologies (BIAF) report related to the accreditation news?

The report was signed on behalf of bioAffinity Technologies, Inc. by Maria Zannes, the company’s President and Chief Executive Officer.

What stock exchange lists bioAffinity Technologies (BIAF) common stock and warrants?

The company’s common stock and warrants to purchase common stock are listed on The Nasdaq Stock Market LLC (Nasdaq Capital Market).